International Journal of Molecular Sciences (Oct 2022)

Anti-Metastatic Effect of Pyruvate Dehydrogenase Kinase 4 Inhibition in Bladder Cancer via the ERK, SRC, and JNK Pathways

  • Eun Hye Lee,
  • Jae-Wook Chung,
  • Eunji Sung,
  • Bo Hyun Yoon,
  • Minji Jeon,
  • Song Park,
  • So Young Chun,
  • Jun Nyung Lee,
  • Bum Soo Kim,
  • Hyun Tae Kim,
  • Tae Hwan Kim,
  • Seock Hwan Choi,
  • Eun Sang Yoo,
  • Tae Gyun Kwon,
  • Ho Won Kang,
  • Wun-Jae Kim,
  • Seok Joong Yun,
  • Sangkyu Lee,
  • Yun-Sok Ha

DOI
https://doi.org/10.3390/ijms232113240
Journal volume & issue
Vol. 23, no. 21
p. 13240

Abstract

Read online

Bladder cancer is a common global cancer with a high percentage of metastases and high mortality rate. Thus, it is necessary to identify new biomarkers that can be helpful in diagnosis. Pyruvate dehydrogenase kinase 4 (PDK4) belongs to the PDK family and plays an important role in glucose utilization in living organisms. In the present study, we evaluated the role of PDK4 in bladder cancer and its related protein changes. First, we observed elevated PDK4 expression in high-grade bladder cancers. To screen for changes in PDK4-related proteins in bladder cancer, we performed a comparative proteomic analysis using PDK4 knockdown cells. In bladder cancer cell lines, PDK4 silencing resulted in a lower rate of cell migration and invasion. In addition, a PDK4 knockdown xenograft model showed reduced bladder cancer growth in nude mice. Based on our results, PDK4 plays a critical role in the metastasis and growth of bladder cancer cells through changes in ERK, SRC, and JNK.

Keywords